These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27251610)

  • 21. Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.
    Ocama P; Seremba E; Apica B; Opio K
    Afr Health Sci; 2015 Jun; 15(2):328-33. PubMed ID: 26124776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of treatment-naive HIV/HBV co-infected patients attending ART clinic of a tertiary healthcare centre in eastern India.
    Saha D; Pal A; Biswas A; Panigrahi R; Sarkar N; Sarkar J; Pal M; Guha SK; Saha B; Chakrabarti S; Chakravarty R
    PLoS One; 2013; 8(8):e73613. PubMed ID: 24023688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians.
    Grant J; Agbaji O; Kramvis A; Yousif M; Auwal M; Penugonda S; Ugoagwu P; Murphy R; Hawkins C
    Trop Med Int Health; 2017 Jun; 22(6):744-754. PubMed ID: 28376292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in a Chinese antiretroviral therapy center.
    Yang R; Gui X; Xiong Y; Gao SC; Yan Y
    Int J Infect Dis; 2014 Nov; 28():29-34. PubMed ID: 25236390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.
    Arendt E; Jaroszewicz J; Rockstroh J; Meyer-Olson D; Zacher BJ; Mederacke I; Manns MP; Wedemeyer H; Cornberg M; Wursthorn K
    Viral Immunol; 2012 Dec; 25(6):442-7. PubMed ID: 23131018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
    Sagoe KW; Agyei AA; Ziga F; Lartey M; Adiku TK; Seshi M; Arens MQ; Mingle JA
    J Med Virol; 2012 Jan; 84(1):6-10. PubMed ID: 22095533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.
    Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C;
    Clin Infect Dis; 2018 Jan; 66(1):112-120. PubMed ID: 29020361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
    Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
    Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.
    Masgala A; Bonovas S; Nikolopoulos GK
    Mini Rev Med Chem; 2012 Aug; 12(9):890-904. PubMed ID: 22530578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.
    Filippini P; Coppola N; Pisapia R; Scolastico C; Marrocco C; Zaccariello A; Nacca C; Sagnelli C; De Stefano G; Ferraro T; De Stefano C; Sagnelli E
    AIDS; 2006 Jun; 20(9):1253-60. PubMed ID: 16816553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection.
    Firnhaber C; Chen CY; Evans D; Maskew M; Schulz D; Reyneke A; Kramvis A
    Int J Infect Dis; 2012 Apr; 16(4):e268-72. PubMed ID: 22305987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycaemic profile changes by highly active antiretroviral therapy in human immunodeficiency virus-infected patients.
    Duro M; Rebelo I; Barreira S; Sarmento-Castro R; Medeiros R; Almeida C
    Int J STD AIDS; 2015 Oct; 26(11):796-802. PubMed ID: 25281540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
    Amponsah-Dacosta E; Rakgole JN; Gededzha MP; Lukhwareni A; Blackard JT; Selabe SG; Mphahlele MJ
    Infect Genet Evol; 2016 Sep; 43():232-8. PubMed ID: 27245151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver function test abnormalities in Nigerian patients with human immunodeficiency virus and hepatitis B virus co-infection.
    Iroezindu MO; Agbaji OO; Daniyam CA; Isiguzo GC; Isichei C; Akanbi MO
    Int J STD AIDS; 2013 Jun; 24(6):461-7. PubMed ID: 23970749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.
    Dong Y; Qiu C; Xia X; Wang J; Zhang H; Zhang X; Xu J
    Arch Virol; 2015 Apr; 160(4):929-36. PubMed ID: 25616842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.